Overview


According to FutureWise analysis the market for cystic fibrosis in 2023 is US$ 12.35 billion, and is expected to reach US$ 71.83 billion by 2031 at a CAGR of 24.62%.

Cystic Fibrosis is a genetic condition that impacts various organs, such as the lungs, pancreas, and digestive system. The condition is a result of mutations in the CFTR gene. The outcome of this endeavour is the inception of a defective protein that disrupts the normal balance of salt and water in the body's cells. This results in thick, sticky mucus that clogs the airways, leading to chronic lung infections and progressive lung damage. The thick, sticky mucus produced by CF can also block the ducts in the pancreas, leading to a reduction in digestive enzymes and insulin production. This can cause malabsorption of nutrients and impaired growth and development, particularly in children.

CF is an inherited disorder; this means that an individual needs to have two copies of the faulty CFTR gene inherited (one from each parent) to develop this disease. Individuals who inherit only one copy of the defective gene are carriers of CF but usually do not show any symptoms. However, carriers can pass on the gene to their children. The symptoms of CF can vary from person to person and can range from mild to severe. In the lungs, the build-up of mucus can lead to chronic coughing, wheezing, and shortness of breath. This can also increase the risk of lung infections, which can lead to progressive lung damage over time. In the digestive system, CF can cause abdominal pain, bloating, diarrhea, and weight loss due to malabsorption of nutrients. CF can also affect the pancreas, leading to diabetes or pancreatitis. In some cases, CF can affect the liver, leading to liver disease or cirrhosis. Treatment for CF aims to manage symptoms, prevent complications, and improve quality of life. This may include airway clearance techniques, antibiotics to treat lung infections, pancreatic enzyme replacement therapy to aid digestion, and nutritional support to maintain adequate nutrient intake.

The CF market has seen significant growth in recent years due to increased understanding of the disease, improved diagnosis rates, and the development of new treatments. An essential element driving the growth of the CF market is the increasing prevalence of the disease. According to the Cystic Fibrosis Foundation, there are an estimated 70,000 people living with CF worldwide, with around 1,000 new cases detected each year in the United States alone. Improved screening and diagnosis methods have also led to earlier detection and treatment of CF, increasing the demand for therapies that can slow disease progression and improve quality of life. Another key factor driving growth in the CF market is the development of new and innovative therapies. The availability of treatments for CF has seen a remarkable surge in recent years, including gene therapies, CFTR modulators, and other targeted therapies. These therapies can effectively address the underlying cause of the disease and significantly improve outcomes for patients with CF.

However, the high cost of CF therapies remains a significant barrier to access for many patients. CF treatments can cost tens of thousands of dollars per year, making them unaffordable for many patients without insurance or with high out-of-pocket costs. This has led to ongoing debates about the pricing of CF therapies and the need for greater transparency and affordability in the healthcare system.

FutureWise Market Research has published a report that provides an insightful analysis of Cystic Fibrosis Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes the stature of key manufacturers operating in this industry. By the end of the forecast period, FutureWise research analysts project that Cystic Fibrosis Market will experience significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, and further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Vertex Pharmaceuticals Incorporated
  • AbbVie Inc.
  • Novartis AG
  • Gilead Sciences, Inc.
  • Mylan NV.
  • Pfizer Inc.
  • Bayer AG
  • Genentech, Inc.  
  • AstraZeneca
  • Alcresta Therapeutics, Inc.
  • F. Hoffmann-La Roche AG

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Class

  • Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
  • Bronchodilators
  • Mucolytic
  • Pancreatic Enzyme Supplement
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. North America is at the forefront of regional growth and a significant revenue provider on a worldwide scale. The region's expansion is being fueled by increased patient awareness of illness remittance treatments, growing CF prevalence, and high public and private healthcare spending. The majority of those affected by CF in the United States are of Caucasian ancestry. Furthermore, measures conducted by the CF Foundation and Cystic Fibrosis Canada are one of the primary reasons for its highest share. Furthermore, easy access to high-quality healthcare, favorable reimbursement policies, a robust clinical pipeline, and the approval of novel drugs are expected to drive revenue growth in North America.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Cystic Fibrosis Market By Drug Class, By Route of Administration, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customisation offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Cystic Fibrosis Market Variables, Trends and Scope
    •        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Product Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Cystic Fibrosis Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Product Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Product Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Cystic Fibrosis Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
        2. Bronchodilators
        3. Mucolytic
        4. Pancreatic Enzyme Supplement
        5. Others

  • 8.   Cystic Fibrosis Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Parenteral

  • 9.   Cystic Fibrosis Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies and Drug Stores
        3. Online Pharmacies

  • 10.   North America Cystic Fibrosis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Cystic Fibrosis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Cystic Fibrosis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Cystic Fibrosis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
                 2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Vertex Pharmaceuticals Incorporated
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. AbbVie Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Novartis AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Gilead Sciences, Inc.
          4.1. Company Overview
          4.2. Product Portfolio
          4.3. SWOT Analysis
          4.4. Financial Overview
          4.5. Strategic Overview
             5. Mylan NV.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
             6. Pfizer Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
             7. Bayer AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
             8. Genentech, Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview 
             9. AstraZeneca
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
             10. Alcresta Therapeutics, Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
             11. F. Hoffmann-La Roche AG 
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients